96 results on '"L. Kodjikian"'
Search Results
2. Kystotomie irienne au laser YAG
- Author
-
A. Rezkallah, A. Alyami, L. Kodjikian, T. Mathis, and P. Denis
- Subjects
Ophthalmology - Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Consensus d’experts français sur les critères de choix d’un traitement de 1re intention dans la DMLA néovasculaire et importance du ratio bénéfice/risque à long terme
- Author
-
A. Couturier, L. Kodjikian, S. Baillif, J.-B. Conart, C. Dot, M.-N. Delyfer, F. Matonti, V. Caillaux, E. Bousquet, A. Robinet, H. Massé, J. Uzzan, S. Mrejen, O. Semoun, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM) more...
- Subjects
medicine.medical_specialty ,Visual acuity ,genetic structures ,business.industry ,Retinal vasculitis ,Delphi method ,Macular degeneration ,medicine.disease ,Vascular occlusion ,eye diseases ,3. Good health ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,030221 ophthalmology & optometry ,Medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Onset of action ,medicine.symptom ,business ,Intensive care medicine ,Adverse effect ,Selection (genetic algorithm) - Abstract
Choosing a first-line treatment to optimize long-term outcomes is a major challenge for treating patients with neovascular age-related macular degeneration (AMD). The development of several new molecules makes it critical to identify the relevant factors to consider so as to provide an optimal risk-benefit ratio when initiating a treatment in naïve patients with neovascular AMD. This paper proposes a consensus established with the Delphi method (which includes a gradation in a consensus based on an analysis of the convergence rate of answers) to provide criteria that guide the ophthalmologist's decision for treatment initiation and follow-up in neovascular AMD patients. Fourteen questions were submitted to 93 French retina experts. Thirteen (93%) of the questions reached a consensus (≥50% of answers consensual). The criteria recommended to take into account were both efficacy and onset of action of the molecules, their safety, and the ability to decrease injection frequency. The primary criterion of expected efficacy of a molecule is a combination of the gain in visual acuity and resorption of retinal fluid. With regard to safety, experts recommend tighter follow-up for molecules currently in development, and at every scheduled visit, patients should be screened to identify early any potential adverse effects such as intraocular inflammation, retinal vasculitis or vascular occlusion. Experts also emphasize the importance of the packaging of the biological, with a preference toward prefilled syringes. Injection frequency is a key factor, and the authors recommended aiming for a maximal injection interval of 12 to 16 weeks. The stability of that maximum interval is also an important factor to consider in treatment selection.; Le choix d’un traitement de 1re intention pour optimiser les résultats à long terme est un enjeu majeur de la prise en charge des patients atteints de DMLA néovasculaire. Dans un contexte actuel de molécules en développement est apparue la nécessité d’identifier les critères indispensables à prendre en compte lors de la mise en place d’un traitement chez un patient naïf atteint de DMLA néovasculaire afin de garantir un rapport bénéfice/risque optimal à long terme. Cet article propose un consensus établi selon la méthodologie de type Delphi (en intégrant une gradation dans les consensus en fonction de l’analyse du taux de convergence des réponses) qui pourrait constituer une aide pour les ophtalmologistes pour l’initiation et le suivi du traitement des patients atteints de DMLA néovasculaire. Quatorze questions ont été soumises à un panel de 93 experts rétinologues français. Treize questions (93 %) ont obtenu un consensus (≥ 50 % de réponses consensuelles). Les experts recommandent ainsi de prendre en compte en priorité l’efficacité et la rapidité d’action respectives des molécules, leur sécurité d’utilisation ainsi que leur capacité d’espacement des injections. Le critère d’efficacité attendu en priorité d’une molécule est la combinaison de l’amélioration de l’acuité visuelle et de l’assèchement des fluides. En matière de sécurité d’utilisation, les experts recommandent une surveillance supplémentaire pour les molécules actuellement en développement, et ce à toutes les visites programmées, visant à détecter précocement d’éventuels effets indésirables tels que l’inflammation intraoculaire et accordent une place importante au conditionnement de la molécule. La capacité d’espacement des injections est importante à prendre en compte et il est recommandé d’atteindre un intervalle maximal compris entre 12 et 16 semaines. La stabilité de l’intervalle maximal atteinte par les patients est également un critère de choix important. more...
- Published
- 2021
- Full Text
- View/download PDF
4. Obstruction d’un MIGS
- Author
-
A. Rezkallah, A. Barbarroux, L. Kodjikian, T. Mathis, and P. Denis
- Subjects
Ophthalmology - Published
- 2022
- Full Text
- View/download PDF
5. Consensus d’experts français sur la mise en œuvre pratique du régime Treat-and-Extend par anti-angiogéniques chez les patients atteints de DMLA exsudative
- Author
-
S. Baillif, C. Creuzot-Garcher, C. Dot, L. Kodjikian, F. Matonti, S. Mrejen, S. Nghiem-Buffet, O. Semoun, and R. Tadayoni
- Subjects
03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,Philosophy ,030221 ophthalmology & optometry ,Treat and extend ,Humanities ,3. Good health - Abstract
Resume L’optimisation des schemas de traitement des anti-angiogeniques est aujourd’hui un enjeu majeur de la prise en charge des patients atteints de DMLA exsudative. L’evolution des approches a conduit les retinologues a privilegier des regimes d’administration dit proactifs, permettant d’anticiper la recidive et de planifier a l’avance les injections intravitreennes d’anti-angiogenique, tel que le Treat-and-Extend. Neanmoins, un reel besoin d’uniformiser l’application de ce schema a ete identifie. Cet article propose un consensus etabli selon la methodologie de type Delphi qui pourrait constituer un guide pour la prise en charge des patients atteints de DMLA exsudative selon le schema d’administration T&E aux ophtalmologistes. Si certains aspects restent a ce jour non consensuels, cet article apporte des elements guidant la mise en œuvre du regime T&E. Les experts recommandent ainsi de realiser une dose de charge comprenant 3 IVT mensuelles en amont de la mise en place du T&E. Ils recommandent aussi d’ajuster les intervalles de reinjections de ± 2 semaines de maniere standard. Les intervalles sont alors diminues en cas de degradation anatomique et/ou fonctionnelle, ils sont maintenus lorsque l’intervalle de recidive est determine, et ils sont augmentes lorsqu’une amelioration anatomique et/ou fonctionnelle est observee. Un intervalle maximal entre 3 et 4 mois est recommande par les experts avec un maintien de l’intervalle maximal durant 1 an avant d’envisager une eventuelle sortie du T&E. En cas de baisse d’acuite visuelle importante liee a la pathologie et d’aggravation anatomique importante, il est recommande de repartir sur des injections mensuelles. En cas d’atteinte bilaterale, lorsqu’une synchronisation des rythmes d’injection des deux yeux est realisee, les experts recommandent de prendre l’intervalle le plus court. more...
- Published
- 2021
- Full Text
- View/download PDF
6. Catégorisation du degré d’urgence selon les actes ou situations en ophtalmologie
- Author
-
Nicolas Leveziel, F. Audrun, J.-R. Fenolland, Sara Touhami, Sabine Defoort, Catherine Vignal, J. Lasudry, Antoine Rousseau, Marie-Noëlle Delyfer, Serge Doan, Bahram Bodaghi, L. Kodjikian, Nathalie Cassoux, P. Denis, Jean-Pierre Caujolle, J.-M. Giraud, C. Zech, C. Arndt, David Saadoun, Valérie Touitou, Claude Speeg-Schatz, and Marc Labetoulle more...
- Subjects
Ophthalmology ,2019-20 coronavirus outbreak ,Categorization ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Applied psychology ,Viral therapy ,Psychology ,Triage ,Degree (music) ,Coronavirus Infections - Published
- 2020
- Full Text
- View/download PDF
7. [Obstructed MIGS]
- Author
-
A, Rezkallah, A, Barbarroux, L, Kodjikian, T, Mathis, and P, Denis
- Subjects
Humans ,Glaucoma ,Intraocular Pressure - Published
- 2022
8. [A bleeding MIGS]
- Author
-
A, Rezkallah, H, Bouvarel, T, Mathis, L, Kodjikian, and P, Denis
- Subjects
Humans ,Glaucoma ,Hemorrhage ,Intraocular Pressure - Published
- 2021
9. [Soemmering's ring on swept-source OCT]
- Author
-
A, Rezkallah, P, Leroux, T, Mathis, L, Kodjikian, and P, Denis
- Subjects
Lens Capsule, Crystalline ,Humans ,Capsule Opacification ,Tomography, Optical Coherence - Published
- 2021
10. [Treatment of exudative age-related macular degeneration: Consensus of French experts for first-line treatment selection and the importance of long-term risk/benefit ratio]
- Author
-
A, Couturier, L, Kodjikian, S, Baillif, J-B, Conart, C, Dot, M-N, Delyfer, F, Matonti, V, Caillaux, E, Bousquet, A, Robinet, H, Massé, J, Uzzan, S, Mrejen, and O, Semoun
- Subjects
Vascular Endothelial Growth Factor A ,Consensus ,Intravitreal Injections ,Visual Acuity ,Wet Macular Degeneration ,Humans ,Angiogenesis Inhibitors ,Risk Assessment - Abstract
Choosing a first-line treatment to optimize long-term outcomes is a major challenge for treating patients with neovascular age-related macular degeneration (AMD). The development of several new molecules makes it critical to identify the relevant factors to consider so as to provide an optimal risk-benefit ratio when initiating a treatment in naïve patients with neovascular AMD. This paper proposes a consensus established with the Delphi method (which includes a gradation in a consensus based on an analysis of the convergence rate of answers) to provide criteria that guide the ophthalmologist's decision for treatment initiation and follow-up in neovascular AMD patients. Fourteen questions were submitted to 93 French retina experts. Thirteen (93%) of the questions reached a consensus (≥50% of answers consensual). The criteria recommended to take into account were both efficacy and onset of action of the molecules, their safety, and the ability to decrease injection frequency. The primary criterion of expected efficacy of a molecule is a combination of the gain in visual acuity and resorption of retinal fluid. With regard to safety, experts recommend tighter follow-up for molecules currently in development, and at every scheduled visit, patients should be screened to identify early any potential adverse effects such as intraocular inflammation, retinal vasculitis or vascular occlusion. Experts also emphasize the importance of the packaging of the biological, with a preference toward prefilled syringes. Injection frequency is a key factor, and the authors recommended aiming for a maximal injection interval of 12 to 16 weeks. The stability of that maximum interval is also an important factor to consider in treatment selection. more...
- Published
- 2021
11. [How to approach management of surgical vitreoretinal disease during the SARS-CoV-2 Covid-19 pandemic?]
- Author
-
C, Arndt, M-N, Delyfer, L, Kodjikian, N, Leveziel, and C, Zech
- Subjects
Vitreous Body ,Betacoronavirus ,Eye Diseases ,Retinal Diseases ,SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Humans ,Ophthalmologic Surgical Procedures ,Emergencies ,Coronavirus Infections ,Pandemics ,Article - Published
- 2020
12. [Categorization of the degree of urgency according to ophthalmology procedures or situations]
- Author
-
C, Arndt, F, Audrun, B, Bodaghi, J-P, Caujolle, N, Cassoux, S, Defoort, M-N, Delyfer, P, Denis, S, Doan, J-R, Fenolland, J-M, Giraud, L, Kodjikian, M, Labetoulle, J, Lasudry, N, Leveziel, A, Rousseau, D, Saadoun, C, Speeg-Schatz, S, Touhami, V, Touitou, C, Vignal, and C, Zech more...
- Subjects
Adult ,Operating Rooms ,Eye Diseases ,Pneumonia, Viral ,Infant, Newborn ,COVID-19 ,Infant ,Ophthalmologic Surgical Procedures ,Severity of Illness Index ,Ophthalmology ,Child, Preschool ,Humans ,Emergencies ,Triage ,Child ,Coronavirus Infections ,Pandemics - Published
- 2020
13. [How to approach follow-up of uveitis patients during the Covid-19 pandemic?]
- Author
-
S, Touhami, D, Saadoun, L, Kodjikian, and B, Bodaghi
- Subjects
SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Antiviral Agents ,Uveitis, Anterior ,Telemedicine ,Article ,Hospitalization ,Uveitis ,Betacoronavirus ,Withholding Treatment ,Recurrence ,Intravitreal Injections ,Ambulatory Care ,Humans ,Steroids ,Coronavirus Infections ,Pandemics ,Immunosuppressive Agents ,Scleritis - Published
- 2020
14. [How to approach intravitreal injections during this COVID-19 pandemic ?]
- Author
-
L, Kodjikian
- Subjects
Diabetic Retinopathy ,SARS-CoV-2 ,Pneumonia, Viral ,Retinal Degeneration ,COVID-19 ,Retinal Neovascularization ,Article ,Betacoronavirus ,Macular Degeneration ,Intravitreal Injections ,Humans ,Emergencies ,Coronavirus Infections ,Pandemics ,Tomography, Optical Coherence - Published
- 2020
15. [Healthcare in the context of Covid-19]
- Author
-
L, Kodjikian
- Subjects
Ophthalmology ,Pneumonia, Viral ,Quarantine ,COVID-19 ,Humans ,Coronavirus Infections ,Delivery of Health Care ,Pandemics - Published
- 2020
16. Un MIGS hémorragique
- Author
-
A. Rezkallah, H. Bouvarel, T. Mathis, L. Kodjikian, and P. Denis
- Subjects
Ophthalmology - Published
- 2022
- Full Text
- View/download PDF
17. [Experts' opinion: Updating good practices for intra-vitreous injection. Recommendations of the French Ophthalmology Societythe French Hospital Hygiene Society]
- Author
-
S-Y, Cohen, L, Kodjikian, F, Devin, M-N, Delyfer, C, Dot, H, Oubraham, S, Razavi, R, Tadayoni, B, Bodaghi, L-S, Aho, A-M, Rogues, M, Soulias-Leveziel, and J-F, Korobelnik
- Subjects
Ophthalmology ,Safety Management ,Intravitreal Injections ,Humans ,Hygiene ,France ,Anesthetics, Local ,Practice Patterns, Physicians' ,Expert Testimony ,Hospitals ,Societies, Medical ,Checklist ,Monitoring, Physiologic - Published
- 2019
18. Une forme de choroïdite serpigineuse maculaire
- Author
-
C Maurin, C Granier, M P Delolme, Frédéric Chiambaretta, and L Kodjikian
- Subjects
03 medical and health sciences ,Ophthalmology ,Choroiditis ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030221 ophthalmology & optometry ,Medicine ,business ,030217 neurology & neurosurgery ,Multifocal choroiditis - Published
- 2016
- Full Text
- View/download PDF
19. [Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]
- Author
-
C, Couret, J-B, Ducloyer, S, Touhami, K, Angioi-Duprez, M-B, Rougier, P, Labalette, C, Titah, I, Cochereau, L, Kodjikian, F, Mura, C, Chiquet, M, Weber, and B, Bodaghi
- Subjects
Panuveitis ,Vision Disorders ,Humans ,Uveitis, Posterior ,Glucocorticoids ,Uveitis, Intermediate ,Immunosuppressive Agents ,Tomography, Optical Coherence - Abstract
Controlling long-term inflammation during non-infectious intermediate, posterior or panuveitis while limiting side effects remains challenging. There is no standardized pre-therapeutic evaluation providing diagnostic certainty, but some simple tests allow us to identifiy the main etiologies. The ophthalmologist identifies the type of uveitis, and the internist completes the investigations according to the ophthalmologist's findings. Fundus photographs, optical coherence tomography, and fluorescein and indocyanine green angiography should be considered during diagnosis and follow-up. Ocular complications of uveitis are numerous. They require close monitoring and specific medical and sometimes surgical management. The growing number of available drugs makes it possible to optimize the management of these conditions with varied etiologies and presentations. Currently, systemic corticosteroids remain the mainstay of therapy, and other alternatives are considered in the case of poor tolerance, steroid resistance or dependence. The choice of a systemic, periocular or intravitreal treatment depends on several factors: chronicity or recurrence of uveitis, duration, bilaterality, association with a systemic inflammatory disease, the presence of contraindications to certain treatments, and also socioeconomic constraints. It is of the utmost importance to find the best compromise allowing tight control of ocular inflammation by means of adapted systemic and/or local treatment while avoiding the main complications. more...
- Published
- 2019
20. [Performance of ultra-wide field retinophotography for screening of diabetic retinopathy]
- Author
-
T, Mathis, T, Lereuil, L, Bruneteau, C, Apoustoulo, C, Vartin, C, Chambard, P, Denis, and L, Kodjikian
- Subjects
Adult ,Aged, 80 and over ,Male ,Diabetic Retinopathy ,Time Factors ,Humans ,Mass Screening ,Female ,Prospective Studies ,Fluorescein Angiography ,Middle Aged ,Sensitivity and Specificity ,Aged - Abstract
Early diagnosis of diabetic retinopathy is a public health issue. Fundus retinophotography (FRP) is widely used for the detection of the disease. Recently, ultra-wide field retinophotography (WFRP) device allows imaging of approximately 80% of the retinal surface in a single image. The goal of the present study was to evaluate the efficacy of WFRP in the diagnosis and gradation of diabetic retinopathy compared to the gold standard of FRP.The non-mydriatic Optos P200Tx was used for WFRP imaging. FRP in the 9 positions of gaze was then acquired with the Topcon TRC-NW6S after pupillary dilation. The processing time for each imaging modality was recorded.One hundred and sixteen eyes of 58 patients were included in this study. Fourteen eyes were excluded from the analysis due to insufficient imaging quality. WFRP sensitivity was 96% and specificity was 92%. Only 6 eyes received a higher severity grade of diabetic retinopathy by WFRP compared to FRP. In these cases, when the WFRP was analyzed in the same field as the FRP, the severity grade was similar for 5 of the 6 eyes. The mean time of acquisition was significantly lower for WFRP compared to FRP.WFRP is fast and effective in screening for diabetic retinopathy. The severity grade of the disease was similar to the gold standard of FRP in most cases. WFRP could thus be used in mass screening for diabetic retinopathy. more...
- Published
- 2018
21. Prise en charge de l’œdème maculaire secondaire à une occlusion veineuse rétinienne
- Author
-
Benjamin Wolff, E. Fourmaux, W. Roquet, L. Kodjikian, David Gaucher, Jean-François Girmens, Stéphanie Baillif, Agnès Glacet-Bernard, S. Nghiêm-Buffet, H. Massé, and Ramin Tadayoni
- Subjects
Gynecology ,medicine.medical_specialty ,Retinal Vein ,business.industry ,Drug Implants ,Treatment outcome ,medicine.disease ,Ophthalmology ,Central retinal vein occlusion ,Occlusion ,medicine ,Branch retinal vein occlusion ,Ranibizumab ,business ,Macular edema ,medicine.drug - Abstract
Resume Contexte Ces dernieres annees, les injections intravitreennes ont complete les modalites de prise en charge des œdemes maculaires (OM) secondaires a une occlusion veineuse retinienne (OVR). Cet article a pour objectif de proposer une mise a jour de la prise en charge de l’OM secondaire a une OVR. Methode Un groupe de travail s’est reuni autour de l’analyse de la litterature effectuee sur Embase/PubMed, sur les traitements des occlusions veineuses ayant une autorisation de mise sur le marche et rembourses sur le territoire francais. Au total, 33 articles ont ete retenus. Un consensus au sein du groupe pour des recommandations basees sur ces donnees de la litterature et leurs experiences cliniques a ete trouve et rapporte dans cet article. Resultats La prise en charge de l’OM secondaire a une occlusion de branche veineuse retinienne (OBVR) ou a une occlusion de veine centrale de la retine (OVCR) differe sur un certain nombre de points. Des modalites de bonnes pratiques de prise en charge ont ainsi ete discutees, separement dans les OBVR et les OVCR, en prenant en compte differents parametres oculaires ou associes. Discussion Le ranibizumab et l’implant de dexamethasone sont des traitements de premiere intention de la baisse visuelle due a l’OM secondaire a une OVR. Le choix de l’un ou l’autre de ces medicaments peut se faire en tenant compte de differents parametres oculaires mais aussi extra-oculaires. Un changement de traitement vers l’un ou l’autre ou vers le laser peut aussi etre envisage durant le suivi. more...
- Published
- 2015
- Full Text
- View/download PDF
22. [Screening for reading difficulties in Parkinson's disease: An evaluation of the Alouette test]
- Author
-
T, Mathis, H, Rauber, L, Sautivet, C, Chambard, P, Denis, T, Danaila, and L, Kodjikian
- Subjects
Male ,Visual Acuity ,Parkinson Disease ,Middle Aged ,Mental Status and Dementia Tests ,Severity of Illness Index ,Pursuit, Smooth ,Dyslexia ,Reading ,Case-Control Studies ,Disease Progression ,Humans ,Mass Screening ,Female ,Aged - Abstract
Reading disorders in Parkinson's disease (PD) are poorly evaluated due to the lack of validated tests to screen for them. They are often attributed to hand tremors associated with the disease. In this study, we evaluated the "alouette test" validated for dyslexia screening, in PD by comparing the results to healthy patients.The "alouette test" was conducted on a fixed surface to avoid errors related to tremor. A fixation and tracking test were then performed. All the tests were filmed to be analyzed later by 2 examiners blinded to the neurological diagnosis.Thirty-eight patients were included, 19 with PD, and 19 healthy age-matched patients. PD patients read on average 250.9±13.7 words correctly vs. 260.3±2.7 words for healthy patients (P=0.008). This difference was greatest for the older patient subgroup (65 years), who had the disease longer (P=0.014). Tracking and fixation tests were more impaired in PD patients compared to healthy patients.This study highlighted many reading disorders in PD. The use of the "alouette test" which can easily be implemented in clinical practice, could help to diagnose these disorders. Better evaluation of these difficulties would allow for better medical care of these patients. more...
- Published
- 2017
23. Real study: Re-treatment evaluated on visual acuity for Lucentis
- Author
-
D, Bellocq, F, De Bats, M, Rabilloud, and L, Kodjikian
- Subjects
Aged, 80 and over ,Male ,Visual Acuity ,Pilot Projects ,Middle Aged ,Retinal Neovascularization ,Macular Degeneration ,Treatment Outcome ,Ranibizumab ,Intravitreal Injections ,Retreatment ,Humans ,Female ,Fluorescein Angiography ,Tomography, Optical Coherence ,Aged - Abstract
To assess the value of a monthly injection of LucentisProspective, single-center, non-controlled trial including naïve AMD patients with neovascularization. An assessment of VA and a spectral domain optical coherence tomography (SD-OCT) were performed at baseline and every month. Monthly injections of LucentisFifteen out of the 21 patients included were anatomically good responders. A mean gain of +14Le (9) was obtained up to the point at which there was no exudation. There was no additional gain from this point until 3 consecutive stable VA results were obtained. During the PRN phase, an additional mean gain of +3.2Le (7.7) was obtained.This initial VA-guided regimen with ranibizumab might prevent the slight decrease in VA observed during the first year of PRN studies. more...
- Published
- 2017
24. [Retinal hemangioblastoma: Treatment strategy and long-term follow-up in a retrospective cohort]
- Author
-
A, Lefevre, T, Mathis, P, Denis, and L, Kodjikian
- Subjects
Adult ,Male ,Laser Coagulation ,Time Factors ,Retinal Neoplasms ,Visual Acuity ,Continuity of Patient Care ,Hemangioblastoma ,Young Adult ,Postoperative Complications ,Cryotherapy ,Humans ,Female ,Follow-Up Studies ,Retrospective Studies - Abstract
Retinal hemangioblastoma (RH) is a benign vascular tumor frequently associated with Von Hippel-Lindau disease (VHL). Tumor growth of RH may lead to deterioration of visual acuity, which can be difficult to treat. Early diagnosis may reduce complication rate and side effects of treatment. The present retrospective study evaluates the long-term follow-up and complications of RH treatment as a function of the therapeutic strategy used.The study included patients with RH, followed at Croix Rousse university hospital, Lyon between 2010 and 2017. The following clinical features were recorded : age at diagnosis, presenting symptom, presence of VHL disease, treatments used, post-therapeutic complications and visual outcomes.Seven eyes of five patients were included in our study. Eighty percent of the patients had a mutation in the VHL gene. Four eyes (57%) were treated with laser photocoagulation and three eyes (43%) were treated with cryotherapy. The mean duration of follow-up was 35 months. One of the eyes treated using laser photocoagulation was complicated by an early epiretinal membrane with no visual consequence. Of the eyes treated by cryoapplication, one was complicated by a vitreous hemorrhage, and another by a rhegmatogenous retinal detachment, both of which resulted in a decrease in visual acuity.The long-term outcome for patients treated for RH was relatively good. Complications were strongly correlated with the initial size of the vascular tumor. Early diagnosis seems to improve visual outcomes. Ophthalmologic monitoring should be part of the systemic, multidisciplinary management. more...
- Published
- 2017
25. Complications oculaires de l’implant esthétique coloré NewColorIris®
- Author
-
Thibaud Mathis, L. Kodjikian, V Fortoul, and P. Denis
- Subjects
Ophthalmology ,business.industry ,Medicine ,business - Published
- 2015
- Full Text
- View/download PDF
26. Les télangiectasies maculaires idiopathiques : aspects cliniques, imagerie et traitements
- Author
-
F. De Bats, L. Kodjikian, and P. Denis
- Subjects
Gynecology ,Anti vegf ,Ophthalmology ,medicine.medical_specialty ,business.industry ,medicine ,Follow up studies ,medicine.disease ,business ,Macular telangiectasia - Abstract
Resume Introduction L’objectif de ce travail est de rappeler les caracteristiques cliniques des telangiectasies maculaires idiopathiques (TMI), l’apport de l’imagerie dans cette pathologie ainsi que les differents moyens therapeutiques dont nous disposons. Patients et methode Il s’agit d’une analyse retrospective concernant les patients ayant presente des TMI diagnostiquees, suivies et traitees a l’hopital de la Croix-Rousse entre juin 2010 et mars 2012. Les aspects fundoscopiques, angiographiques (AGF), cliches en autofluorescence, et en tomographie a coherence optique en spectral domaine a haute resolution (SD-OCT) ont permis de diagnostiquer et classer ces TMI en deux groupes. Les patients presentant une baisse d’acuite visuelle secondaire a un œdeme maculaire cystoide ont ete traites par laser et/ou injection intravitreenne d’anti-VEGF. Resultats L’association de l’AGF et du SD-OCT a permis de diagnostiquer deux patients presentant des TMI de groupe 1 et deux patients des TMI de groupe 2. Nous avons retrouve une efficacite fonctionnelle et anatomique du traitement par anti-VEGF dans les TMI de groupe 1. Discussion La physiopathologie des TMI est complexe. Les anti-VEGF semblent etre une alternative efficace pour le traitement de l’œdeme maculaire cystoide secondaire aux TMI de groupe 1. Conclusion Il existe encore de nombreuses incertitudes quant a la physiopathologie et le traitement des telangiectasies maculaires idiopathiques. Pour traiter l’œdeme maculaire cystoide associe aux TMI de groupe 1, les anti-VEGF, hors AMM dans cette indication, semblent etre efficaces au prix de plusieurs reinjections. Il ne semble pas exister de traitement efficace pour les TMI de groupe 2 sans complication neovasculaire. Les progres therapeutiques dont va beneficier la DMLA atrophique pourront probablement etre efficaces dans cette indication. more...
- Published
- 2013
- Full Text
- View/download PDF
27. Néovaisseaux choroïdiens du myope fort naïfs traités par injections intravitréennes de bévacizumab : résultats à plus de 12 mois
- Author
-
J.D. Grange, F. De Bats, P. Denis, and L. Kodjikian
- Subjects
Ophthalmology - Abstract
Resume Introduction La myopie forte est la premiere cause de neovascularisation choroidienne chez les patients de moins de 50 ans. Malgre l’absence d’etude prospective, l’injection intravitreenne d’anti-VEGF est largement utilisee dans cette indication. Le but de ce travail est d’evaluer l’efficacite du bevacizumab en injections intravitreennes utilise en premiere intention pour le traitement de neovaisseaux choroidiens retro- et juxtafoveolaires du myope fort. Patients et methodes Nous rapportons les resultats d’une etude retrospective incluant les patients myopes forts atteints de neovaisseaux retro- et juxtafoveolaires traites en premiere intention par injections intravitreennes de 1,25 mg (0,05 cm 3 ) de bevacizumab ou Avastin ® a l’hopital de la Croix-Rousse, Lyon, entre janvier 2009 et juin 2010. La visite initiale comportait pour chaque patient un interrogatoire a la recherche d’un syndrome maculaire, une mesure de l’acuite visuelle, une mesure de la pression intraoculaire, un fond d’œil, une angiographie a la fluoresceine et une optical coherence tomography (OCT) maculaire. Les patients etaient suivis chaque mois et retraites en cas de persistance ou recidive de l’exsudation neovasculaire. Resultats Huit yeux de huit patients presentant un neovaisseau choroidien naif de tout traitement ont ete traites et suivis au minimum 12 mois avec un suivi moyen de 19 mois. L’âge moyen des patients etait de 49 ans avec une erreur refractive moyenne de −11 dioptries. Dans 75 % des cas, une fibrose du neovaisseau a ete obtenue a 12 mois pour une moyenne de trois injections. A un an, tous les patients sauf un avaient stabilise ou ameliore leur vision. Les metamorphopsies avaient disparu dans plus de 50 % des cas apres la premiere injection et dans 100 % des cas a un an. Aucun effet indesirable n’a ete constate au cours du suivi. Conclusion Dans ce travail, l’injection intravitreenne de bevacizumab ou Avastin ® semble efficace et bien toleree dans le traitement des neovaisseaux choroidiens retro- et juxtafoveolaires naifs du myope fort. Il persiste, cependant, de nombreuses incertitudes quant a l’utilisation hors AMM des anti-VEGF dans cette indication. Des etudes prospectives a grande echelle pourront peut-etre, un jour, nous apporter des reponses plus precises. more...
- Published
- 2013
- Full Text
- View/download PDF
28. [Rational treatment of exudative AMD: Request for therapeutic uniform practice. The 'knowtreat']
- Author
-
F, Devin and L, Kodjikian
- Subjects
Rationalization ,Vascular Endothelial Growth Factor A ,Health Knowledge, Attitudes, Practice ,Macular Degeneration ,Ophthalmology ,Evidence-Based Practice ,Intravitreal Injections ,Practice Guidelines as Topic ,Wet Macular Degeneration ,Aftercare ,Humans ,Reference Standards ,Watchful Waiting - Published
- 2016
29. [Individualized management of patients with exudative AMD, IOI protocol: Injection-observational-individualization]
- Author
-
O, Semoun, S Y, Cohen, M, Srour, C, Creuzot-Garchet, H, Oubraham-Mebroukine, L, Kodjikian, F, Devin, and E H, Souied
- Subjects
Aged, 80 and over ,Intravitreal Injections ,Practice Guidelines as Topic ,Wet Macular Degeneration ,Humans ,France ,Middle Aged ,Practice Patterns, Physicians' ,Precision Medicine ,Aged ,Monitoring, Physiologic - Abstract
Wet macular degeneration remains a major cause of visual impairment in people over 55years. Through a group of experts belonging to the Federation France Macula, we review the treatment of wet AMD and provide recommendation with a 3 phases protocol called IOI. more...
- Published
- 2016
30. [Management algorithm of age-related macular degeneration with aflibercept: Real-life application]
- Author
-
V, Gualino, S, Baillif, and L, Kodjikian
- Subjects
Macular Degeneration ,Receptors, Vascular Endothelial Growth Factor ,Recombinant Fusion Proteins ,Intravitreal Injections ,Humans ,Angiogenesis Inhibitors ,France ,Practice Patterns, Physicians' ,Algorithms - Abstract
Aflibercept is indicated in France for wet age-related macular degeneration (wAMD) since November 2013. Its official dosage consists in administrating one monthly intravitreal injection (IVT) during three months followed by one control visit and one IVT every two months the first year. In 2015, a group of French ophthalmologists, specialized in wAMD management, established a therapeutic algorithm to optimize naive patient management with aflibercept in order to obtain visual acuity gain. It indicates that official administration scheme is adapted for 80% of patients and that an adaptation of therapeutic scheme is needed for others. These experts recommended mostly the use of personalized proactive administration scheme. Since, aflibercept clinical use has significantly grown with interventional observational studies which results are now available. Use of aflibercept and of personalized proactive administration schemes allow in real-life obtaining important visual acuity gain, which is consistent with the established algorithm. more...
- Published
- 2016
31. Techniques d’analyse génomique du mélanome uvéal : une revue bibliographique
- Author
-
Jérôme Couturier, L. Kodjikian, and N. Abi-Ayad
- Subjects
Ophthalmology ,Biology ,Molecular biology - Abstract
Resume Le facteur biologique du melanome uveal le plus pertinent sur le plan pronostique semble etre l’etude du genome et du transcriptome de la tumeur. Pour cela, les techniques d’analyse sont nombreuses : a travers une revue de la litterature, nous avons voulu evaluer leur capacite a detecter les patients a haut risque metastatique. Le caryotype, l’hybridation in situ en fluorescence et l’analyse de microsatellites ne sont pas suffisantes. Les techniques d’analyse de l’ADN tumoral doivent etudier l’ensemble du genome (hybridation genomique comparative, [CGH]), et, de facon optimale, detecter l’isodisomie du chromosome 3 ( single nucleotid polymorphism sur puce, SNP-array). L’amplification multiplex de sondes nucleiques dependant de ligatures (MLPA) est une alternative moins couteuse, mais parfois d’interpretation moins aisee, a la CGH-array. L’analyse du transcriptome de la tumeur, encore d’un cout eleve, est la plus performante pour predire l’evolution defavorable du patient. Ces outils diagnostiques permettraient de selectionner precisement les patients a haut risque metastatique pour les inclure dans des protocoles de traitements adjuvants a venir. more...
- Published
- 2011
- Full Text
- View/download PDF
32. Apport de l’analyse par hybridation comparative génomique dans le mélanome uvéal : étude de dix cas énucléés
- Author
-
L. Kodjikian, A. Calender, M. Devouassoux-Shisheboran, N. Abi-Ayad, Jérôme Couturier, and Jean-Daniel Grange
- Subjects
Gynecology ,03 medical and health sciences ,Ophthalmology ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,030221 ophthalmology & optometry ,medicine ,Uveal Neoplasm ,business - Abstract
Resume Objectif Detecter les anomalies chromosomiques majeures du melanome uveal enuclee, les correler a la survenue de metastases hepatiques et au deces. Patients et methodes Dix melanomes uveaux enuclees entre 2005 et 2008 a l’hopital de la Croix-Rousse de Lyon ont ete analyses retrospectivement par hybridation comparative genomique sur puce pangenomique 19 000 clones. Resultats Les desequilibres les plus frequents etaient une perte du chromosome 3 (8/10), un gain du 8q (7/10) ou du 8 entier (2/10) et un gain du 6p (2/10). La plupart des metastases (6/7) et tous les cas de deces (5/5) concernaient les tumeurs ayant la monosomie du chromosome 3 associee a un gain de 8q. Discussion et conclusion L’hybridation genomique comparative sur puce est une technique d’analyse pangenomique adaptee a l’etude du melanome uveal. La monosomie du chromosome 3, associee aux gains de 8q, sont frequents et fortement correles au mauvais pronostic de la tumeur. Les gains de 6q sont rares et de meilleur pronostic. Les desequilibres chromosomiques portant sur les chromosomes 3 et 6 sont mutuellement exclusifs dans notre serie. Ces donnees vont dans le sens de celles decrites dans la litterature. more...
- Published
- 2011
- Full Text
- View/download PDF
33. Imagerie multimodale d’un ostéome choroïdien décalcifié
- Author
-
A.-S. Marty, F. Debats, L. Kodjikian, and P. Denis
- Subjects
Ophthalmology - Published
- 2014
- Full Text
- View/download PDF
34. Uvéite bilatérale induite par la rifabutine : à propos d’un cas
- Author
-
Fathalah Benbouzid, P. Denis, A M Nguyen, L. Kodjikian, C Pochat-Cotilloux, Ariane Malclès, and F. De Bats
- Subjects
Ophthalmology ,business.industry ,Medicine ,business - Published
- 2014
- Full Text
- View/download PDF
35. Toxoplasmose et grossesse
- Author
-
L. Kodjikian
- Subjects
Pediatrics ,medicine.medical_specialty ,Pregnancy ,Transplacental transmission ,biology ,business.industry ,Incidence (epidemiology) ,Toxoplasma gondii ,Azithromycin ,medicine.disease ,biology.organism_classification ,Toxoplasmosis ,3. Good health ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,030225 pediatrics ,030221 ophthalmology & optometry ,Etiology ,medicine ,Seroprevalence ,business ,medicine.drug - Abstract
Toxoplasmosis is the most common etiology of posterior uveitis. Toxoplasma gondii infection during pregnancy means either primary infection and risk of congenital toxoplasmosis or acute retinochoroiditis in a pregnant woman (risk of transmission, severity of injuries, therapeutics). Ingestion or manipulation of raw or undercooked meat is responsible for most contaminations (one- to two-thirds) in pregnant women. Toxoplasmosis seroprevalence is high in Europe, up to 54 % in southern European countries. Primary prevention advice is proposed to immunocompetent pregnant women who are seronegative for toxoplasmosis. The risk of transplacental transmission congenital toxoplasmosis during pregnancy is analyzed. The ocular lesions include retinochoroiditis and a number of other lesions. The departments of ophthalmology and of parasitology of Croix-Rousse University Hospital (Hospices Civils de Lyon) is currently following one of the largest cohorts of children infected with T. gondii (430 children alive in 2005). Our overall transmission rate during primary infection was 30 %. Retinochoroiditis incidence was 24 % in our prospective cohort. During follow-up, recurrences appeared in 29 % of cases. Acute toxoplasmic retinochoroiditis in pregnancy could be a risk of transplacental transmission due to potential parasitemia. Practices in cases of suspected or proved congenital infection are discussed. The antiparasitic drugs authorized during pregnancy are azithromycin and pyrimethamine. Azithromycin can be used alone but an association with pyrimethamine during the second trimester is useful in case of macular threat. more...
- Published
- 2010
- Full Text
- View/download PDF
36. [Diabetic macular edema: Diagnosis and pre-treatment work-up]
- Author
-
P, Massin, S, Baillif, C, Creuzot, F, Fajnkuchen, and L, Kodjikian
- Subjects
Diabetic Retinopathy ,Humans ,Macular Edema - Published
- 2015
37. [Physician information sheet: Treatment of diabetic macular edema]
- Author
-
P, Massin, S, Baillif, C, Creuzot, F, Fajnkuchen, and L, Kodjikian
- Subjects
Diabetic Retinopathy ,Humans ,Macular Edema - Published
- 2015
38. [Treatment of age-related macular degeneration: Expert opinion and therapeutic algorithm]
- Author
-
L, Kodjikian, E, Fourmaux, F, Coscas, S, Dumas, C, Français, C, Morel, H, Oubraham, and S, Razavi
- Subjects
Aged, 80 and over ,Recombinant Fusion Proteins ,Remission Induction ,Visual Acuity ,Disease Management ,Angiogenesis Inhibitors ,Middle Aged ,Choroidal Neovascularization ,Drug Administration Schedule ,Maintenance Chemotherapy ,Macular Degeneration ,Receptors, Vascular Endothelial Growth Factor ,Intravitreal Injections ,Practice Guidelines as Topic ,Humans ,Algorithms ,Aged - Abstract
Intravitreal injections (IVT) of aflibercept are indicated in France for the treatment of neovascular age-related macular degeneration (AMD). An induction phase consisting of 3 monthly IVTs followed by follow-up visits and IVTs every other month during the first year is recommended. However, it may be necessary to adjust this schedule for some patients who might benefit from a more tailored approach, namely a follow-up visit immediately after the induction phase. The goal was to develop a treatment algorithm that would reflect current clinical experience and the opinions of experts on neovascular AMD.A group of retinologists took positions on therapeutic questions regarding management of AMD using a nominal group technique (NGT). The results were combined to create a treatment algorithm.Seventy-nine percent of experts considered that the approved schedule was efficacious when fluid was completely resorbed after the induction phase. Ninety-four percent of experts recommended, after a successful induction phase, a monthly follow-up visit for 3 to 6 months in order to determine the rhythm of recurrence for each patient. Ninety-six percent of experts recommended that persistent fluid after the induction phase, even if visual acuity is improved satisfactorily, should be a criterion for systematic retreatment.The proposed algorithm (expert opinion) after the first year of use of aflibercept in France captures the complexity of the clinical cases that exist in daily practice and the necessity for regular follow-ups. more...
- Published
- 2015
39. Syndrome des taches blanches multiples évanescentes (MEWDS)
- Author
-
L Kodjikian, N Abi-Ayad, and N Prince
- Subjects
Ophthalmology ,medicine.medical_specialty ,business.industry ,MEDLINE ,medicine ,business ,Dermatology - Published
- 2011
- Full Text
- View/download PDF
40. [Management of macular edema secondary to retinal vein occlusion]
- Author
-
J-F, Girmens, A, Glacet-Bernard, L, Kodjikian, S, Nghiêm-Buffet, H, Massé, E, Fourmaux, B, Wolff, W, Roquet, D, Gaucher, S, Baillif, and R, Tadayoni
- Subjects
Drug Implants ,Consensus ,Treatment Outcome ,Ranibizumab ,Intravitreal Injections ,Retinal Vein Occlusion ,Humans ,Dexamethasone ,Macular Edema - Abstract
In recent years, intravitreal injections have added to the treatment modalities available for macular edema (ME) secondary to retinal vein occlusion (RVO). This article aims to provide an update regarding the management of ME secondary to RVO.A work group met in order to analyze the literature available on Embase/PubMed, regarding treatments for venous occlusion that have received market approval and are reimbursed in France. In total, 33 articles were selected. Consensus within the group for recommendations was based on this data from the literature review and clinical experience and was reported in this article.The management of ME secondary to branch retinal vein occlusion (BRVO) or central vein occlusion of the retina (CRVO) differs on a number of points. Methods of best practice were discussed separately for BRVO and CRVO, taking into account various ocular and associated parameters.Ranibizumab and dexamethasone implant are the first-line treatments for visual impairment due to ME secondary to RVO. The choice of either of these drugs may take into account various ocular and extraocular parameters. A change of treatment to one or the other or to laser may also be considered during follow-up. more...
- Published
- 2014
41. [Combined cilioretinal artery and central retinal vein occlusion complicating sleep apnea syndrome]
- Author
-
A, Malclès, F, De Bats, L, Kodjikian, and P, Denis
- Subjects
Adult ,Sleep Apnea, Obstructive ,Retinal Diseases ,Retinal Artery Occlusion ,Humans ,Female ,Scotoma ,Retinal Vein ,Ciliary Arteries - Published
- 2014
42. [Classification of vitreomacular adhesion and macular holes]
- Author
-
Y, Le Mer, J-F, Korobelnik, L, Kodjikian, C, Creuzot-Garcher, M, Weber, F, Devin, J-C, Zech, S Y, Cohen, and R, Tadayoni
- Subjects
Vitreous Body ,Eye Diseases ,Humans ,Retinal Perforations ,Tomography, Optical Coherence - Abstract
Optical coherence tomography has significantly changed the approach to vitreomacular diseases, including macular holes (MH). OCT provides information on differential diagnoses (lamellar hole, pseudo-hole), the MH size, the status of the vitreous, and the status of the various retinal layers. The evolution of diagnostic tools and treatment justifies the need for an update of the current classification of vitreomacular diseases.A group of retina specialists met several times to discuss the international classification, recently published by The International Vitreomacular Traction Study Group, focusing on vitreomacular adhesion (VMA), vitreomacular traction (VMT) and MH. It was compared to the classification currently used in France, based on the ophthalmoscopic system of Gass, then further delineated by Gaudric's OCT studies, in order to suggest a French adaptation to the international classification.An adapted classification for clinical use in France and in connection with the international classification is proposed. VMA are classified as an "associated" or "isolated" VMA respectively with or without macular disease. MH are distinguished as "primary" or "secondary" MH depending on whether the etiology is known or not, and classified as "small", "medium" and "large" depending on the size of the hole, and according to the presence or absence of VMT. Finally, VMT are described according to presence or absence of an epimacular membrane and according to the width of the adhesion. more...
- Published
- 2014
43. [Multimodal fundus imaging in decalcified choroidal osteoma]
- Author
-
A-S, Marty, F, Debats, L, Kodjikian, and P, Denis
- Subjects
Adult ,Choroid Neoplasms ,Decalcification, Pathologic ,Humans ,Osteoma ,Bone Neoplasms ,Female ,Fluorescein Angiography ,Multimodal Imaging ,Tomography, Optical Coherence - Published
- 2014
44. [Retinal arterial macroanevrysm complicated by a branch retinal artery occlusion]
- Author
-
A-S, Marty, F, Debats, L, Kodjikian, and P, Denis
- Subjects
Aged, 80 and over ,Retinal Artery ,Retinal Artery Occlusion ,Humans ,Female ,Aneurysm - Published
- 2013
45. [Neovascular glaucoma treatment in 2012: role of anti-VEGF agents]
- Author
-
L, Kodjikian
- Subjects
Bevacizumab ,Glaucoma, Neovascular ,Vascular Endothelial Growth Factor A ,Ophthalmology ,Humans ,Angiogenesis Inhibitors ,Antibodies, Monoclonal, Humanized ,Models, Biological - Abstract
Neovascular glaucoma is a serious pathology with a variety of causes. It results from the secretion by hypoxic retinal tissue of growth factors, including vascular endothelial growth factor (VEGF). Anterior segment involvement begins in the iris, followed by the development of a fibrovascular membrane in the angle, with resultant goniosynechiae. Treatment of the underlying disease consists most often of panretinal photocoagulation. As for the secondary sequelae, current treatment consists of intravitreal injection of anti-VEGF agents. The most utilized agent is bevacizumab or Avastin, off-label. Avastin is effective against neovascularization and ocular hypertension, especially in the early stages. It also represents an adjunct to filtering surgery. It appears to be very well tolerated. more...
- Published
- 2012
46. [Anomalous retinal vascular pattern]
- Author
-
F, De Bats, P, Denis, and L, Kodjikian
- Subjects
Male ,Humans ,Retinal Vessels ,Epiretinal Membrane ,Fluorescein Angiography - Published
- 2012
47. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients
- Author
-
P.L. Cornut, Carole Burillon, A. Feldman, P. Denis, L. Kodjikian, J.D. Grange, and F. De Bats
- Subjects
Male ,medicine.medical_specialty ,Visual acuity ,genetic structures ,Bevacizumab ,Angiogenesis Inhibitors ,Antibodies, Monoclonal, Humanized ,Macular Degeneration ,Ophthalmology ,Ranibizumab ,Medicine ,Humans ,Adverse effect ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Macular degeneration ,medicine.disease ,Exudative age-related macular degeneration ,eye diseases ,Choroidal neovascularization ,Case-Control Studies ,Optometry ,Female ,sense organs ,medicine.symptom ,business ,medicine.drug - Abstract
Summary Aim To compare the efficacy and safety of bevacizumab versus ranibizumab in the treatment of patients with neovascular age-related macular degeneration (AMD). Patients and methods Retrospective case-controlled series of 30 patients treated with intravitreal bevacizumab and 28 patients treated with intravitreal ranibizumab for exudative AMD. Main outcomes measured included best-corrected visual acuity (BCVA), central macular thickness (CMT) and foveal thickness, quantity of subretinal fluid, neovessel size and total number of injections over the first year treatment period. A secondary outcome was the report of any adverse events in both groups. Results BCVA stabilized and increased from LogMAR 0.70 to 0.47 in the bevacizumab group and from 0.55 to 0.54 in the ranibizumab group ( P > 0.05). CMT decreased in the bevacizumab group from 369 to 284 μm and in the ranibizumab group from 340 to 271 μm ( P > 0.05). The number of injection was significantly lower (4.8) in the bevacizumab group than in the ranibizumab group (5.8) ( P Conclusion This retrospective study failed to show a difference in visual and anatomic outcomes between bevacizumab and ranibizumab. The number of re-treatment was lower in the bevacizumab group ( P = 0.03). more...
- Published
- 2011
48. Macroanévrysme artériel rétinien compliqué d’une occlusion de branche de l’artère centrale de la rétine
- Author
-
A.-S. Marty, P. Denis, L. Kodjikian, and F. Debats
- Subjects
Ophthalmology - Published
- 2014
- Full Text
- View/download PDF
49. [Multiple evanescent white dot syndrome (MEWDS)]
- Author
-
N, Abi-Ayad, N, Prince, and L, Kodjikian
- Subjects
Adolescent ,Retinal Diseases ,Humans ,Female ,Choroid Diseases ,Syndrome - Published
- 2010
50. [Imaging of YAG laser treatment for Valsalva retinopathy]
- Author
-
N, Abi-Ayad and L, Kodjikian
- Subjects
Male ,Ophthalmoscopy ,Fundus Oculi ,Valsalva Maneuver ,Humans ,Retinal Hemorrhage ,Laser Therapy ,Lasers, Solid-State ,Middle Aged - Published
- 2010
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.